BGNE BeiGene Ltd.

125
+0.54  (+0%)
Previous Close 124.46
Open 125
Price To Book 4.29
Market Cap 7455528875
Shares 59,644,231
Volume 147,049
Short Ratio
Av. Daily Volume 280,004

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced January 2, 2018.
Tislelizumab
Hepatocellular carcinoma (HCC)
Phase 2 pivotal trial initiation announced December 18, 2017.
BGB-290
Ovarian Cancer
Phase 3 data from 17p del cohort due 2H 2019.
Zanubrutinib (BGB-3111) with Bendamustine Plus Rituximab
First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 2 pivotal trial initiation announced November 13, 2017.
BGB-3111 in combination with GAZYVA (obinutuzumab)
Follicular lymphoma (FL)
Phase 3 trial to be initiated 1H 2018.
Pamiparib (BGB-290)
Solid tumors - cancer
Phase 2 pivotial China trial initiation announced July 5, 2017.
BGB-A317
Urothelial cancer (UC) - bladder cancer
Phase 2 data at ASH 2018 noted ORR 86%; CR 61%.
Tislelizumab - BGB-A317
Relapsed or refractory classical Hodgkin lymphoma (cHL)
Phase 2 updated data due 1H 2019.
Zanubrutinib (BGB-3111)
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 data to be presented 1H 2019.
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab - BGB-A317
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 data due 2019.
Tislelizumab
Hepatocellular carcinoma (HCC) - second-line
Phase 3 trial initiation announced July 24, 2018.
Pamiparib (BGB-290)
Gastric Cancer
Phase 1/2 data from ongoing trial presented at ESMO-IO December 14, 2018. 1/17 CRs 4/17 PRs.
Tislelizumab
Urothelial carcinoma - Bladder cancer
Phase 3 trial commencement of enrollment announced May 17, 2018.
Pamiparib (BGB-290)
Maintenance Therapy Ovarian Cancer
Phase 3 trial initiation announced July 24, 2018.
Tislelizumab
Non-squamous non-small cell lung cancer (NSCLC)
Phase 3 trial initiation announced August 9, 2018.
Tislelizumab
Squamous non-small cell lung cancer (NSCLC)
Phase 1/2 data presented at SNO November 16, 2018 noted 2/15 partial responses.
Pamiparib (BGB-290)
Glioblastoma (GBM)
Phase 3 data due 2H 2019.
Zanubrutinib (BGB-3111) vs Ibrutinib
Refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1b initial data due 2H 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab
Gastric Cancer
Phase 1 updated data due 1H 2019.
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 2 trial initiation announced February 19, 2019.
Zanubrutinib (BGB-3111) - MAGNOLIA
Marginal Zone Lymphoma

Latest News

  1. 3 Key Takeaways From BeiGene's CEO
  2. Be cautious about the market now — and buy these 3 stocks on weakness
  3. BRIEF-Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics
  4. Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
  5. Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson — Fundamental Analysis, Key Performance Indications
  6. BeiGene to Present at Upcoming Investor Conferences
  7. Edited Transcript of BGNE earnings conference call or presentation 27-Feb-19 11:00pm GMT
  8. Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
  9. Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
  10. Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat
  11. BRIEF-Beigene Reports Qtrly Loss Per Share Of $0.35
  12. BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
  13. BeiGene Ltd. Sponsored ADR to Host Earnings Call
  14. BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference
  15. Have Insiders Been Selling BeiGene, Ltd. (NASDAQ:BGNE) Shares?
  16. BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
  17. Market Trends Toward New Normal in CenturyLink, Textainer Group, BeiGene, Nova Measuring Instruments, One Liberty Properties, and Westwood Holdings Group — Emerging Consolidated Expectations, Analyst Ratings
  18. BeiGene, Ltd. (BGNE) Upgraded to Strong Buy: Here's What You Should Know
  19. BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong
  20. BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day